Charles Schwab
PMVP icon

Charles Schwab’s PMV Pharmaceuticals PMVP Stock Holding History

Charles Schwab’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-178,592
Closed -$289K – 3561
2024
Q2 		$289K Sell
178,592
-87,332
-33% -$158K ﹤0.01% 3375
2024
Q1 		$452K Buy
265,924
+7,397
+3% +$13.8K ﹤0.01% 3066
2023
Q4 		$801K Sell
258,527
-11,070
-4% -$29.3K ﹤0.01% 2907
2023
Q3 		$1.66M Buy
269,597
+9,755
+4% +$67.1K ﹤0.01% 2658
2023
Q2 		$1.63M Buy
259,842
+6,368
+3% +$33.4K ﹤0.01% 2616
2023
Q1 		$1.21M Buy
253,474
+1,515
+0.6% +$10.7K ﹤0.01% 2678
2022
Q4 		$2.19M Buy
251,959
+3,483
+1% +$37.1K ﹤0.01% 2542
2022
Q3 		$2.96M Buy
248,476
+35,579
+17% +$514K ﹤0.01% 2466
2022
Q2 		$3.03M Buy
212,897
+18,021
+9% +$262K ﹤0.01% 2410
2022
Q1 		$4.06M Buy
194,876
+5,097
+3% +$89.9K ﹤0.01% 2377
2021
Q4 		$4.38M Buy
189,779
+2,616
+1% +$63.2K ﹤0.01% 2411
2021
Q3 		$5.58M Buy
187,163
+72,875
+64% +$2.33M ﹤0.01% 2323
2021
Q2 		$3.9M Buy
114,288
+29,203
+34% +$975K ﹤0.01% 2467
2021
Q1 		$2.8M Buy
85,085
+1,921
+2% +$75.7K ﹤0.01% 2552
2020
Q4 		$5.12M Buy
+83,164
New +$3.26M ﹤0.01% 2199

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's PMVP Position: Q3 2024 in Review

Charles Schwab sold out of PMV Pharmaceuticals (PMVP) in Q3 2024, closing a stake of 178,592 shares — an estimated $289K sold.

Charles Schwab first reported a position in PMVP in Q4 2020 and held it in 15 quarters. The position peaked at $5.58M in Q3 2021. 74 funds tracked by Wall St. Rank hold PMVP as of Q3 2024.

  • Charles Schwab reported no remaining PMV Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 178,592 PMV Pharmaceuticals shares in Q3 2024, an estimated $289K.
  • Charles Schwab first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 15 quarters.
  • Charles Schwab's PMV Pharmaceuticals position peaked at $5.58M in Q3 2021.
  • 74 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.